• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, PK and PD of exoIL-12-a novel engineered exosome therapeutic candidate

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Mitchell, J.
    Scarisbrick, J.
    De Francesco, I.
    Cowan, Richard A
    McKay, P.
    Osborne, W.
    Sathyanarayanan, S.
    Ascolillo, L.
    Gow, I.
    Hill, W.
    Lorch, U.
    Sorensen, B.
    Show allShow less
    Affiliation
    Richmond Pharmacology, London,
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background: Interleukin-12 is an active cytokine for cancer treatment, however the full potential has yet to be realized despite extensive exploration of dose, schedule, and route and method of administration. These approaches have been limited by systemic exposure, resulting in serious adverse events (SAEs) and/or unpredictable pharmacology. exoIL-12™ is a novel, engineered-exosome that displays functional IL-12 on the surface and is designed for local intra-tumoral administration and retention. Objectives of the study: A Phase 1 study in two parts is being conducted. Part A was a randomized placebo-controlled, single ascending dose trial in healthy volunteers to investigate safety, tolerability and both local and systemic pharmacokinetics (PK) and pharmacodynamics (PD). Methodology: A total of 25 male subjects across 5 cohorts were enrolled and randomized 3:2 to exoIL-12 vs placebo. Study drug was administered subcutaneously to each of the 5 cohorts at dose levels of exoIL-12 of 0.3, 1.0, 3.0, 6.0 and 12.0 µg, respectively. Study subjects were admitted to a Phase 1 unit on day -1 and discharged on day 2 and followed for safety and tolerability until day 29. PK and PD assessments included IL-12, IFNγ and IP-10 levels in plasma and IL-12 and IP-10 in serial skin punch biopsies surrounding the injection site. Results: No SAEs were observed. Only mild AEs were recorded. of the AEs were considered related to the study drug. exoIL-12 demonstrated no systemic IL-12 exposure. All blood samples showed IL-12 levels below the limit of quantification (8 pg/mL) at all dose levels. Confirmation of local retention of IL-12 will be assessed by measurement of IL-12 levels in skin punch biopsies pre-treatment and at 24 hrs, day 8 and day 15 post treatment. Systemic and local pharmacodynamic effects will be assessed by quantifying IP-10 levels in serial blood samples and skin punch biopsies. Conclusions: Studies of recombinant IL-12 conducted by others in healthy volunteers at comparable dose levels to the present study resulted in dose dependent systemic IL-12 exposure as well as IFNγ and IP-10 production and common adverse events such as fever, chills, myalgia, headache, and muscle pain. In contrast, exoIL-12 demonstrated a favorable safety and tolerability profile with no treatment-related adverse events and no systemic IL-12 exposure. Local IL-12 levels in the skin as well as pharmacodynamic data from blood and skin samples will be presented. The study is advancing into Part B, an open label study of exoIL-12 in patients with cutaneous T-cell lymphoma.
    Citation
    Mitchell J, Scarisbrick J, De Francesco I, Cowan R, McKay P, Osborne W, et al. Abstract CT114: Randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, PK and PD of exoIL-12 - a novel engineered exosome therapeutic candidate. In: Clinical Trials. American Association for Cancer Research; 2021.
    Journal
    Cancer Research
    URI
    http://hdl.handle.net/10541/624621
    DOI
    10.1158/1538-7445.AM2021-CT114
    Additional Links
    https://dx.doi.org/10.1158/1538-7445.AM2021-CT114
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1158/1538-7445.AM2021-CT114
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.